FR3108032B1 - Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes - Google Patents
Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes Download PDFInfo
- Publication number
- FR3108032B1 FR3108032B1 FR2002476A FR2002476A FR3108032B1 FR 3108032 B1 FR3108032 B1 FR 3108032B1 FR 2002476 A FR2002476 A FR 2002476A FR 2002476 A FR2002476 A FR 2002476A FR 3108032 B1 FR3108032 B1 FR 3108032B1
- Authority
- FR
- France
- Prior art keywords
- ligament
- muscle
- prevention
- treatment
- physical activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010066371 Tendon pain Diseases 0.000 title abstract 2
- 210000003041 ligament Anatomy 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 210000003205 muscle Anatomy 0.000 title abstract 2
- 230000037081 physical activity Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 206010068790 Ligament pain Diseases 0.000 title 1
- 208000000112 Myalgia Diseases 0.000 title 1
- 208000013465 muscle pain Diseases 0.000 title 1
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L’invention porte sur le nicotinamide mononucléotide, un de ses dérivés pharmaceutiquement acceptables ou un de ses sels pharmaceutiquement acceptables, pour son utilisation dans la prévention et/ou le traitement d’une douleur musculaire, ligamentaire, tendineuse ou leurs combinaisons, induite par l’activité physique ainsi que les compositions le comprenant.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2002476A FR3108032B1 (fr) | 2020-03-12 | 2020-03-12 | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
US17/910,655 US20230149435A1 (en) | 2020-03-12 | 2021-03-12 | Use of nmn for the prevention and/or treatment of muscle, ligament or tendon pain induced by physical activity and corresponding compositions |
CN202180032717.2A CN115551516A (zh) | 2020-03-12 | 2021-03-12 | 烟酰胺单核苷酸或其某些衍生物用于预防和/或治疗由身体活动引起的肌肉、韧带或肌腱疼痛的用途,以及相应的组合物 |
AU2021235134A AU2021235134A1 (en) | 2020-03-12 | 2021-03-12 | Use of a nicotinamide mononucleotide or some of its derivatives for the prevention and/or treatment of muscle, ligament or tendon pain induced by physical activity, and corresponding compositions |
EP21710504.8A EP4117675A1 (fr) | 2020-03-12 | 2021-03-12 | Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur musculaire, ligamentaire ou tendineuse induite par l'activite physique, et compositions correspondantes |
JP2022555100A JP2023517109A (ja) | 2020-03-12 | 2021-03-12 | 身体的活動によって誘発される筋肉、靭帯または腱の痛みを予防および/または治療するためのニコチンアミドモノヌクレオチドまたはその誘導体のいくつかの使用、ならびに対応する組成物 |
CA3175090A CA3175090A1 (fr) | 2020-03-12 | 2021-03-12 | Utilisation de nicotinamide mononucleotide ou de certains de ses derives pour la prevention et/ou le traitement d'une douleur musculaire, ligamentaire ou tendineuse induite par l' activite physique, et compositions correspondantes |
PCT/EP2021/056319 WO2021180916A1 (fr) | 2020-03-12 | 2021-03-12 | Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur musculaire, ligamentaire ou tendineuse induite par l'activite physique, et compositions correspondantes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR2002476A FR3108032B1 (fr) | 2020-03-12 | 2020-03-12 | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
FR2002476 | 2020-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
FR3108032A1 FR3108032A1 (fr) | 2021-09-17 |
FR3108032B1 true FR3108032B1 (fr) | 2024-02-16 |
Family
ID=71661991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR2002476A Active FR3108032B1 (fr) | 2020-03-12 | 2020-03-12 | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230149435A1 (fr) |
EP (1) | EP4117675A1 (fr) |
JP (1) | JP2023517109A (fr) |
CN (1) | CN115551516A (fr) |
AU (1) | AU2021235134A1 (fr) |
CA (1) | CA3175090A1 (fr) |
FR (1) | FR3108032B1 (fr) |
WO (1) | WO2021180916A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4070799A1 (fr) * | 2021-04-08 | 2022-10-12 | Nuvamid SA | Compositions pour l'amélioration des performances sportives |
CN113817009B (zh) * | 2021-11-23 | 2022-06-03 | 中立安(北京)医药科技有限公司 | 烟酰胺单核苷类衍生物及其制备方法和应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
US20150283163A1 (en) * | 2014-04-04 | 2015-10-08 | Organic Medical Ventures, L.L.C. | Muscle treatment composition and method making same |
MX2016016071A (es) * | 2014-06-06 | 2017-07-11 | Glaxosmithkline Intellectual Property (No 2) Ltd | Analogos de ribosido de nicotinamida y composiciones farmaceuticas y usos de los mismos. |
PT3288637T (pt) * | 2015-04-28 | 2022-10-11 | Newsouth Innovations Pty Ltd | Visar nad+ para tratar comprometimento cognitivo, neuropatias e inatividade induzidos por quimioterapia e radioterapia |
US9855289B2 (en) | 2015-08-05 | 2018-01-02 | Metro International Biotech, Llc | Nicotinamide mononucleotide derivatives and their uses |
US10611790B2 (en) | 2015-11-02 | 2020-04-07 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
US20170165282A1 (en) * | 2015-12-11 | 2017-06-15 | Bontac Bio-Engineering (Shenzhen) Co., Ltd. | Use of beta-nicotinamide mononucleotide in preparation of drugs for preventing and treating arteriosclerosis and cardio-cerebrovascular diseases, and drugs containing the same |
CN107233352A (zh) * | 2017-06-20 | 2017-10-10 | 同济大学 | 烟酰胺腺嘌呤二核苷酸在制备治疗炎性痛药物中的应用 |
FR3106056B1 (fr) * | 2020-01-13 | 2021-12-17 | Nuvamid | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes |
-
2020
- 2020-03-12 FR FR2002476A patent/FR3108032B1/fr active Active
-
2021
- 2021-03-12 CN CN202180032717.2A patent/CN115551516A/zh active Pending
- 2021-03-12 EP EP21710504.8A patent/EP4117675A1/fr active Pending
- 2021-03-12 JP JP2022555100A patent/JP2023517109A/ja active Pending
- 2021-03-12 AU AU2021235134A patent/AU2021235134A1/en active Pending
- 2021-03-12 WO PCT/EP2021/056319 patent/WO2021180916A1/fr unknown
- 2021-03-12 US US17/910,655 patent/US20230149435A1/en active Pending
- 2021-03-12 CA CA3175090A patent/CA3175090A1/fr active Pending
Also Published As
Publication number | Publication date |
---|---|
CN115551516A (zh) | 2022-12-30 |
CA3175090A1 (fr) | 2021-09-16 |
JP2023517109A (ja) | 2023-04-21 |
FR3108032A1 (fr) | 2021-09-17 |
US20230149435A1 (en) | 2023-05-18 |
EP4117675A1 (fr) | 2023-01-18 |
WO2021180916A1 (fr) | 2021-09-16 |
AU2021235134A1 (en) | 2022-10-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Iwamoto et al. | Effectiveness of exercise for osteoarthritis of the knee: A review of the literature | |
Fietzek et al. | Early botulinum toxin treatment for spastic pes equinovarus–a randomized double‐blind placebo‐controlled study | |
Duman et al. | Assessment of the impact of proprioceptive exercises on balance and proprioception in patients with advanced knee osteoarthritis | |
MA42410A (fr) | Oxystérols et leurs méthodes d'utilisation | |
MA33730B1 (fr) | Procédés de synthèse pour des composés spiro-oxindoles | |
FR3108032B1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur musculaire, ligamentaire ou tendineuse induite par l’activité physique et compositions correspondantes | |
MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
BRPI0416212A (pt) | derivado de piridazinona, composição farmacêutica, uso do derivado, método para o tratamento de um sujeito afligido com uma condição ou doença susceptìvel de melhora pela inibição de fosfodiesterase 4 e produto de combinação | |
BR0317717A (pt) | Composto, composição farmacêutica, uso de um composto, método para tratar um humano sofrendo de uma doença, e, processo para a preparação de um composto | |
MA38648B1 (fr) | Composés carboxamide de carbazole et de tétrahydrocarbazole substitués convenant comme inhibiteurs de kinases | |
TNSN07476A1 (fr) | Derives de n-(pyridine -2- yl) - sulfonamide | |
BRPI0514736A (pt) | inibidores do receptor sigma | |
DK1735278T3 (da) | Histamin H3-receptormidler, fremstilling og terapeutiske anvendelser | |
MA34474B1 (fr) | Agonistes de gpr40 | |
BRPI0508254A (pt) | métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos | |
ATE485037T1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
BR112022022578A2 (pt) | Novas composições e métodos de tratar doença covid-19 | |
BR112022015151A2 (pt) | Método para reduzir ou prevenir progressão de um tumor ou tratar câncer, e, composição | |
MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
Van Ooteghem et al. | Postural motor learning in Parkinson’s disease: The effect of practice on continuous compensatory postural regulation | |
FR3106056B1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement d’une douleur articulaire induite par l’activité physique et compositions correspondantes | |
MA38425A1 (fr) | Composés bicycliques pour une utilisation comme agonistes selectifs pour le recepteur s1p1 | |
BR112021023110A2 (pt) | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
BR112023016631A2 (pt) | Inibidores de apol1 e métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PLFP | Fee payment |
Year of fee payment: 2 |
|
PLSC | Publication of the preliminary search report |
Effective date: 20210917 |
|
PLFP | Fee payment |
Year of fee payment: 3 |
|
PLFP | Fee payment |
Year of fee payment: 4 |
|
PLFP | Fee payment |
Year of fee payment: 5 |